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Abstract
Objectives—To identify the types of cancer patients admitted to inpatient medical rehabilitation 
and to describe their rehabilitation outcomes. Design: Retrospective cohort study.
Setting—U.S. inpatient rehabilitation facilities (IRFs).
Participants—Adult patients (N=27,952) with a malignant cancer diagnosis admitted to an IRF 
with a cancer-related impairment between October 2010 and September 2012 were identified from 
the Uniform Data System for Medical Rehabilitation database.
Interventions—Not applicable.
Main Outcome Measures—Demographic, medical, and rehabilitation characteristics for 
patients with various cancer tumor types were summarized using data collected from the Inpatient 
Rehabilitation Facility–Patient Assessment Instrument. Rehabilitation outcomes included the 
percentage of patients discharged to the community and acute care settings, and functional change 
from admission to discharge. Functional status was measured using the FIM instrument.
Results—Cancer patients constituted about 2.4% of the total IRF patient population. Cancer 
types included brain and nervous system (52.9%), digestive (12.0%), bone and joint (8.7%), blood 
and lymphatic (7.6%), respiratory (7.1%), and other (11.7%). Overall, 72% were discharged to a 
community setting, and 16.5% were discharged back to acute care. Patients with blood and 
lymphatic cancers had the highest frequency of discharge back to acute care (28%). On average, 
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all cancer patient groups made significant functional gains during their IRF stay (mean FIM total 
change ± SD, 23.5±16.2).
Conclusions—In a database representing approximately 70% of all U.S. patients in IRFs, we 
found that patients with a variety of cancer types are admitted to inpatient rehabilitation. Most 
cancer patients admitted to IRFs were discharged to a community setting and, on average, 
improved their function. Future research is warranted to understand the referral patterns of 
admission to postacute care rehabilitation and to identify factors that are associated with 
rehabilitation benefit in order to inform the establishment of appropriate care protocols.
Keywords
Hospitalization; Neoplasms; Rehabilitation; Survivors
Cancer is a chronic disease and a major source of morbidity and mortality in the United 
States. Increasing cancer incidence, coupled with an aging population, has vastly increased 
cancer prevalence. Currently, there are approximately 14.5 million cancer survivors living in 
the United States.1 It is estimated that there will be 18 million by 2022.2 In addition, the 5-
year survival rates for all cancer types has increased from 49% during the years of 1975 to 
1977, to 69% during 2005 to 2011.1 Although cancer patients are surviving longer, many 
have physical and cognitive impairments resulting from the etiology of cancer and from 
cancer treatments such as surgery, chemotherapy, radio-therapy, and hormonal therapy.3 
Common types of impairments in cancer patients include pain, fatigue, neurologic 
dysfunction, bone metastasis, soft tissue disruption, sexual dysfunction, and cognitive 
deficits.4 These conditions can appear suddenly, but can also be a gradual accumulation of 
multiple disease and treatment effects.3
The American College of Surgeons Commission on Cancer requires accredited facilities to 
ensure that cancer patients have access to rehabilitation services and that a survivorship care 
plan is developed for comprehensive cancer care.5 However, standard guidelines for follow-
up care among cancer survivors do not currently exist,6 and there is increased recognition 
that an increase in the coordination of care among cancer survivors is needed.7 
Rehabilitation services are widely underused among cancer patients,8 and many patients 
with functional disability needs do not receive postacute rehabilitative care.8–10
Patients with diagnosed cancer are more likely to report poorer health outcomes, have a 
higher burden of illness, and a lower physical and mental quality of life than patients without 
cancer.11,12 Among cancer survivors, poor physical quality of life is reported more 
frequently than poor mental quality of life,12 and patient distress is strongly related to 
impaired physical functioning.11 Rehabilitation programs may serve to improve functional 
capacity lost as a result of cancer etiology and treatment. Early intervention through 
participation in comprehensive rehabilitation therapies across the care continuum may be 
effective in restoring functional deficits and preventing long-term disability related to cancer.
3
Inpatient rehabilitation facilities (IRFs) provide interdisciplinary postacute care inpatient 
rehabilitation services consisting of medical management, physical therapy, occupational 
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therapy, and speech-language therapy. The goal of IRF care is to restore or improve function 
and to help patients achieve a level of independence that allows them to return to a 
community setting. Admission to an IRF requires the patient to be medically stable and able 
to tolerate a minimum of 3 hours of therapy per day for at least 5 days per week.13 For 
cancer patients, IRF care focuses on addressing acute physical impairments related to 
treatment.3
There is little known about the characteristics of cancer patients receiving inpatient 
rehabilitation services. A better understanding of the types of cancer patients that present to 
inpatient rehabilitation and their outcomes could inform targeted approaches to address their 
functional needs and enhance management of complex disease sequelae. In this study, we 
describe the demographic, medical, and rehabilitation characteristics of cancer patients who 
were admitted to U.S. IRFs over a 3-year period using a large national database. We 
hypothesized that there would be differences in demographic characteristics as well as 
rehabilitation outcomes between patients with different tumor types.
Methods
Study design and population
We conducted a retrospective cohort study using 3 years of de-identified data from the 
Uniform Data System for Medical Rehabilitation (UDSMR) database. The UDSMR 
maintains the world’s largest nongovernmental database for rehabilitation outcomes14 and 
includes data from more than 70% of the IRFs in the United States. The dataset includes 
demographic, medical, and rehabilitation data collected from the Inpatient Rehabilitation 
Facility–Patient Assessment Instrument (IRF-PAI). These data are collected from each 
patient at admission and discharge from the participating IRF, and data collection procedures 
are standardized for all facilities.15
The inclusion and exclusion criteria for the study population are depicted in figure 1. In 
these analyses, patients were included if they were at least 18 years of age, admitted to the 
IRF for an initial rehabilitation visit, and discharged between October 2010 and September 
2012. Some IRFs in the UDSMR database were exempt from the prospective payment 
system and were not subject to the requirements regarding data collection and reporting time 
frames associated with the IRF-PAI (n=16 institutions). Patients seen in those facilities were 
excluded from the analysis (n=27,828). In addition, patients were excluded if they were 
discharged against medical advice (n=5792) or if they died while in the IRF (n=1895).
Patients with malignant cancers were identified and classified according to the International 
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes 140–
209.36 and 209.72–209.79, abstracted from the etiologic diagnosis code field on the IRF-
PAI. Patients with a benign or in situ tumor were excluded from the sample. Cancer patients 
were excluded if they were admitted for a rehabilitation impairment that was not associated 
with their cancer diagnosis or treatment. These conditions included traumatic brain injury, 
multiple sclerosis, Parkinson disease, Guillain-Barré syndrome, cerebral palsy, traumatic 
spinal cord injury, arthritis, hip and knee replacements, burn injury, congenital deformities, 
major multiple trauma, and developmental disability. In addition to examination of the entire 
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group of cancer patients, we examined characteristics by cancer subgroups. Cancer sites 
were determined by ICD-9-CM code and included brain and nervous system, digestive, bone 
and joint, blood and lymphatic, respiratory, and other cancers. This study was approved by 
the Institutional Review Board of the University at Buffalo.
Study variables
Demographic, medical, and rehabilitation characteristics were examined. Demographic 
variables included age (years), race (white, black, other), marital status (married, not 
married), employment status before admission to the hospital (employed, not employed, 
retired), prehospital living setting (community, long-term care, acute care, rehabilitation, 
other), and living situation before hospitalization (living alone, living with others). Medical 
and rehabilitation variables considered included rehabilitation impairment type (brain 
dysfunction, debility, spinal cord dysfunction, medically complex condition, and other 
impairments), impairment onset days to rehabilitation (defined as the time between the onset 
of the impairment needing rehabilitation and admission to the rehabilitation facility), length 
of stay in inpatient rehabilitation, mobility status at admission (walking, wheelchair, or 
both), and Centers for Medicare and Medicaid Services comorbidity tier (tier A, no cost; tier 
B, high cost; tier C, moderate cost; tier D, low cost). Up to 10 comorbid condition codes can 
be indicated on the IRF-PAI using ICD-9-CM codes. Comorbidities are defined as 
conditions reported at admission to the IRF that affect the principal diagnosis or 
rehabilitation impairment. Patients in comorbidity tier A do not have comorbidities that 
significantly affect resource utilization, or have comorbid conditions of the least severity. 
Tier B patients have the most severe comorbidities, tier C have moderately severe 
comorbidities, and tier D have mild comorbidities.
Functional independence was measured using the FIM instrument (“FIM”). This instrument 
measures the severity of disability of patients by rating their ability to perform basic life 
activities. It includes 18 items in 2 major domains (motor, cognitive) and 6 subdomains 
(self-care, sphincter control, transfers, locomotion, communication, social cognition). Motor 
items include eating, grooming, bathing, dressing upper body, dressing lower body, toileting, 
bladder control, bowel control, bed/chair/wheelchair transfers, toilet transfers, tub/shower 
transfers, walking/wheelchair locomotion, and stair climbing. Cognitive items include 
comprehension, expression, social interaction, problem solving, and memory. Each item is 
rated on a scale from 1 (complete dependence) to 7 (complete independence). The scores for 
the 18 items are summed, resulting in a composite score ranging from 18 to 126, with higher 
scores reflecting greater functional independence.
Functional variables derived from the FIM instrument include FIM admission total, FIM 
discharge total, FIM change, and length of stay efficiency. These rehabilitation outcome 
measures have been used in studies16–21 of other inpatient rehabilitation patient populations. 
Admission FIM total and discharge FIM total are the total summed ratings derived at 
admission and discharge, respectively. FIM change is the difference between the FIM 
discharge rating and the FIM admission rating and is an indicator of functional improvement 
over the course of inpatient rehabilitation. Length of stay efficiency is calculated as FIM 
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change divided by the rehabilitation length of stay, and is interpreted as FIM points gained 
per day, broadly reflecting a measure of the efficiency of inpatient rehabilitation.
Statistical analysis
Demographic, medical, and rehabilitation variables were summarized using means and SDs 
for continuous variables and frequency counts and percentages for categorical variables. To 
test the differences in admission FIM total, discharge FIM total, rehabilitation length of stay, 
and length of stay efficiency between cancer subgroups, analysis of variance was used. 
Analysis of variance was also used to test the difference in FIM subdomain scores between 
cancer patient groups. Chi-square tests were used to test the differences in discharge to the 
community setting and discharge to the acute care setting between cancer subgroups. A P 
value of <.05 was considered statistically significant. Data were analyzed using SPSS 
version 22.a
Results
A total of 27,952 patients with malignant cancer were identified from among the 1,155,690 
patients who met inclusion/exclusion criteria. Prevalence of cancer categories among 
patients are shown in figure 2. Cancer patients were grouped into the following categories: 
brain and nervous system cancers (52.9%), digestive system cancers (12.0%), bone and joint 
cancers (8.7%), blood and lymphatic cancers (7.6%), respiratory system cancers (7.1%), and 
other cancers (11.7%). Demographic and medical characteristics of the study sample are 
shown in table 1. The mean age ± SD of the overall cancer population was 65.1±14.1 years, 
52% were men, 79% were white, 58% were married, 66% were retired before 
hospitalization, 59% had Medicare as the primary insurance payer, and 78% were living 
with others before hospitalization. Patients with digestive or respiratory cancers and those in 
the group of other cancers tended to be older, most likely as a result of an older average age 
at diagnosis for those cancer types. Cancer patients were admitted most frequently for 
impairments related to brain dysfunction (48%), debility (24%), and spinal cord dysfunction 
(12%). Most cancer patients (81%) were walking at admission to the IRF. There was a 
median of 9 days (interquartile range, 9d) between the onset of the rehabilitation impairment 
and admission to the IRF.
Rehabilitation characteristics are shown in table 2. On average, cancer patients had a mean ± 
SD admission FIM total score of 65.1±14.1, were discharged with a mean ± SD FIM total 
score of 84.7±22.1, and gained approximately a mean ± SD of 23.5±16.2 FIM points over 
the course of inpatient rehabilitation. Cancer patients had a mean ± SD length of stay of 
12.6±7.4 days in the inpatient rehabilitation unit and gained a mean of 2.2 FIM points per 
day. Analysis of variance test results indicated that there were significant differences 
between cancer subgroups with regard to admission FIM total (F5,27946=151.9, P<.001; r=.
16), discharge FIM total (F5,27946=187.8, P<.001; r=.18), FIM total change (F5,27946=78.2, 
P<.001; r=.12), rehabilitation length of stay (F5,27946=96.2, P<.001; r=.13), and length of 
stay efficiency (F5,27946=117.2, P<.001; r=.14). Patients with brain and nervous system 
aSPSS version 22; IBM Corp.
Mix et al. Page 5
Arch Phys Med Rehabil. Author manuscript; available in PMC 2018 July 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
cancers were most functionally dependent on admission (mean admission FIM total, 58.9), 
whereas patients with respiratory cancers had higher functional scores (mean admission FIM 
total, 66.4). Patients with digestive cancers made the largest functional gains during their 
rehabilitation stay (mean FIM total change, 26.9). On average, all cancer patient groups 
made meaningful functional change over the course of inpatient rehabilitation. 
Approximately 72% of cancer patients admitted to inpatient rehabilitation were discharged 
to a community setting, and 16.5% were discharged to an acute care setting. Blood and 
lymphatic cancer patients experienced the lowest discharge to community (62%) and the 
highest average discharge to acute care settings (28.4%). Age, admission FIM total, 
discharge FIM total, FIM gain, and discharge to the community setting are summarized for 
each tumor site in table 3. FIM score changes for cancer patients ranged from 17.5 to 32.5 
points gained, and rates of discharge to the community ranged from 44.4% to 100%.
The FIM ratings for functional subdomains of the FIM instrument by cancer type are 
displayed in table 4. Analysis of variance test results were significant for all FIM 
subdomains, with statistically significant differences between cancer subgroups between 
self-care (F5,27946=95.1, P<.001; r=.13), sphincter control (F5,27946=18.9, P<.001; r=.06), 
mobility (F5,27946=70.0, P<.001; r=.11), locomotion (F5,27946=60.2, P<.001; r=.10), 
communication (F5,27946=33.9, P<.001; r=.08), and the social interaction domains 
(F5,27946=26.3, P<.001; r=.07). Large qualitative differences in the functional subdomains of 
the FIM instrument between cancer groups were not present. However, patients with 
digestive cancers had the greatest FIM change in all subdomains.
Discussion
We examined demographic, medical, and rehabilitation characteristics of cancer patients in a 
study sample that included most of the patients admitted to IRFs in the United States. We 
found that patients with cancer in our study made clinically significant functional 
improvement from admission to discharge, with a mean gain in FIM total score of 23.5 
points. Beninato et al22 found that a difference of 22 between the FIM at admission and 
discharge among stroke patients was the smallest increment with clinical significance. 
Wallace et al23 also reported on the minimal clinically important difference among stroke 
patients and found that a motor FIM change score of 11 points was clinically important; 
patients with cancer in our study made changes in FIM of this magnitude on average. 
Previous research has indicated that a 1-point increase in the total FIM instrument rating is 
associated with a reduction of 3 to 6 minutes of care-giver help per day, which on average 
would equate to approximately 1 to 2 hours less of caregiver help per day in our sample.
24–27
 Although previous work on the clinical meaningfulness of the FIM instrument is based 
on patients with various diseases, these guidelines provide a reference point for the clinical 
utility of inpatient rehabilitation in cancer patients. Our results provide a useful framework 
for clinicians and hospital administrators for setting appropriate goals and expectations for 
functional outcomes among cancer patients admitted to inpatient rehabilitation programs.
Our findings are consistent with previous smaller studies performed among cancer patients 
in IRFs, which have shown positive functional improvement. Marciniak et al28 performed a 
retrospective chart review of 159 patients with a variety of cancer diagnoses and found 
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significant functional gains in mean motor FIM total from admission to discharge (42.6 vs 
56.0, P<.001). All cancer groups examined in the study (brain, breast, spinal cord, other) 
experienced similar functional improvements and efficiency in functional gain. In a study29 
of 200 cancer patients, significant functional improvements from admission to discharge 
were reported, with equivalent motor and cognitive gains across all 9 cancer subgroups. In 
studies30–34 of patients with brain tumors, patients were shown to make significant 
functional improvement from admission to discharge. Significant functional gains have also 
been reported for patients with malignant spinal cord compression35 and cancer-related 
asthenia.36 Given the predisposition for marked functional debility among patients with 
cancer, the observed functional improvement reported after inpatient rehabilitation has 
important implications for therapeutic efficacy during cancer treatment as well as for 
enhanced quality of life thereafter. Furthermore, a few small studies37–40 suggest that 
functional improvement is associated with prolonged survival for cancer patients.
Because of the recent Hospital Readmissions Reduction Program provision of the 
Affordable Care Act,41 the prevention of hospital readmissions and the identification of 
factors predictive of rehospitalization are increasingly important to medical institutions. 
Reported readmission rates among cancer patients in inpatient rehabilitation in the United 
States have ranged from 17% to 35%.8,42–44 We found that among all cancer patients in our 
cohort, 16% were discharged to acute care. In addition, we also found that patients with 
blood and lymphatic cancers were most likely to be discharged back to the acute care setting 
(28%); other studies8,44,45 have also reported leukemia and lymphoma patients as having a 
higher likelihood of discharge from inpatient rehabilitation to acute care settings (33% and 
38%, respectively). However, we do not have data as to how many of these cancer patients 
would have been readmitted to acute care if they had not received the inpatient 
rehabilitation, nor do we know how many of these readmissions were planned for additional 
cancer treatment. Future study in this population should focus on understanding the 
predictors of unplanned discharges to acute care from inpatient rehabilitation.
The characteristics of cancer patients seen in IRFs do not reflect the general population of 
cancer patients, particularly in regards to tumor type. Patients are admitted to IRFs for 
functional impairments that require intensive inpatient rehabilitation with medical 
management. Patients must meet certain eligibility criteria that include medical stability, the 
need for intensive rehabilitation therapies, and the ability to tolerate rehabilitation therapy at 
the required duration. Cancer patients without the need for more than one rehabilitation 
therapy, or those who have unrecognized impairments in acute care would be less likely to 
be referred to an IRF. The high percentage of patients with brain and nervous system cancer 
in this sample reflects the higher burden of physical and cognitive disabilities that 
accompany these diagnoses, and the higher likelihood that these patients were referred to 
IRFs. In addition, restrictions related to Medicare reimbursement may limit admission of 
cancer patients to IRFs who do not have rehabilitation impairments that qualify for the IRF 
compliance threshold.8
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Study limitations
Potential limitations of these data are important to consider when interpreting these findings. 
This study was a retrospective study limited to the variables collected on the IRF-PAI, and to 
the quality of methods used to obtain this information across multiple institutions. The IRF-
PAI did not include information regarding the details of the cancer diagnosis. Specifically, 
primary and metastatic cancer cases were not differentiated. While there may be differences 
in outcomes between primary and metastatic cancers, there is evidence that cancer patients 
are able to make functional improvements even with metastatic lesions.28,33,46 In addition, 
we were unable to examine the influence of tumor characteristics such as stage and grade, as 
well as type of cancer treatment received, on rehabilitation outcomes. However, there is 
evidence that receiving cancer treatments during rehabilitation does not impede functional 
progress.28,46 We were unable to determine if the type of rehabilitation therapy or the 
frequency or duration of rehabilitation therapy was related to cancer type, as this data was 
not available.
Another limitation in the interpretation of the results of this study is that most of the study 
population is white (79%). This lack of diversity in our sample brings forth several potential 
issues for consideration including referral bias, inequity of health insurance, and cultural 
factors that may favor other forms of rehabilitation care outside the inpatient setting. 
Research in other patient populations has suggested that minority patients are less likely to 
use postacute care47 and are less likely to be discharged to inpatient rehabilitation.48 In 
addition, rehabilitation outcomes have been reported to differ between racial and ethnic 
groups in inpatient rehabilitation populations.49,50 Further research needs to be performed to 
explore variables that influence racial and ethnic disparities in cancer rehabilitation research 
in order to improve health care access, quality, and outcomes.
An important strength of this study is its size and generaliz-ability to cancer patients 
admitted to IRFs. The UDSMR dataset is unique in that it includes data collected from more 
than 70% of the IRFs in the United States. Cancer patients represent a little more than 2% of 
the IRF population; there were close to 28,000 cancer patients in our analytic sample over a 
3-year period. In addition, detailed standardized data on functional status are collected at 
admission and discharge from the IRF, and extensive training and credentialing protocols are 
followed to ensure reproducibility of the measurement across institutions. The validity and 
reliability of the FIM instrument have been demonstrated in previous studies. In a meta-
analysis of 11 studies published between 1993 and 1995 with a total sample of 1568 patients 
with various diagnoses, Ottenbacher et al51 reported a median z-transformed interrater 
reliability coefficient of .95 for the FIM total rating. In addition, the FIM total rating has 
been shown to be negatively correlated with the amount of time required from a caregiver to 
assist the patient in performing activities of daily living in the home setting.24,25,27,52 These 
data provide information with significant clinical implications regarding expectations for 
functional improvement in cancer patients. Although previous studies on this topic exist, 
they have been at single institution settings with smaller sample sizes. The larger volume of 
data in this examination helps to corroborate findings of previous studies and also provides 
useful benchmarking information for rehabilitation outcomes in a variety of cancer types.
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Conclusions
The prevalence of cancer survivors in the United States is expected to continue to increase 
with the aging population. At present, cancer patients constitute more than 2% of patients 
seen in IRFs, a proportion that could grow as the population ages, as treatment of cancer 
allows for an increased number of survivors. We found that most of the cancer patients with 
malignant tumors admitted to an inpatient rehabilitation program were discharged to a 
community setting and, on average, were able to make functional improvements during their 
IRF stay. Future research is warranted to understand the referral patterns of admission to 
postacute care rehabilitation and to identify factors that are associated with rehabilitation 
benefit. Increased awareness is needed among cancer care professionals of the potential for 
improving function in cancer patients.
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Fig 1. 
Study population inclusion and exclusion criteria of the UDSMR dataset, October 2010 
through September 2012. Abbreviation: ICD, International Classification of Diseases.
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Fig 2. 
Distribution of cancer patients in U.S. IRFs, October 2010 through September 2012 
(N=27,952).
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